Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OICR-9429 is a potent antagonist of the interaction that WDR5 effect with peptide regions of MLL and Histone 3. It reduces the viability of acute myeloid leukemia cells in vitro.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
2 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 68.00 | |
10 mg | In stock | $ 113.00 | |
25 mg | In stock | $ 197.00 | |
50 mg | In stock | $ 328.00 | |
100 mg | In stock | $ 528.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 98.00 |
Description | OICR-9429 is a potent antagonist of the interaction that WDR5 effect with peptide regions of MLL and Histone 3. It reduces the viability of acute myeloid leukemia cells in vitro. |
Targets&IC50 | WDR5:93 nM(Kd) |
In vitro | OICR-9429 binds WDR5 with high affinity (Kd=93±28 nM) and competitively disrupts its interaction with a high-affinity Wdr5-interacting (WIN) peptide of MLL (Kdisp=64±4 nM)[1]. |
Kinase Assay | AR binding affinity: AR binding affinities of test compounds are studied in cytosolic lysates obtained from ventral prostates of castrated rats by a competition binding assay. Fresh prostates are minced and homogenized with Buffer A containing protease inhibitors. The homogenates are centrifuged and the resultant supernatants are treated with a dextran-coated charcoal solution to remove endogenous steroids. The dissociation constant of the radio ligand [3H]mibolerone for isolated rat ARs is determined in a saturation binding experiment. For the determination of Ki values, prostate cytosol preparations and 1?nM [3H]mibolerone are incubated with increasing concentrations of test compounds overnight. After the incubation, bound and free steroids are separated by treatment with 100?μL of dextran-coated charcoal suspension. Bound radioactivity is determined by counting 100?μL of supernatant fraction in 200?μL of scintillation fluid using a microbeta counter. All procedures are carried out at 0–4?°C. |
Cell Research | 20,000 viable, actively proliferating primary human AML cells per well were seeded in 96-well plates in triplicates and treated with 0.05% DMSO or OICR-9429. Cell viability was measured using the Cell Titer-Glo luminescent cell viability assay on a VICTOR X4 luminometer after 72 h.(Only for Reference) |
Synonyms | OICR 9429 |
Molecular Weight | 555.59 |
Formula | C29H32F3N5O3 |
CAS No. | 1801787-56-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 38 mg/mL (68.39 mM)
Ethanol: 12 mg/mL(21.6 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
OICR-9429 1801787-56-3 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells Histone Methyltransferase JAK pancreatic MLL inhibit colon prostate cance OICR9429 bladder cancer (BCa) Inhibitor WD repeat domain 5 (WDR5) Apoptosis leukaemia H3K4 OICR 9429 inhibitor